Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 3/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17099081 | 1.00 | CCR5 (0.34) | CCR5NR3C1POLBMAPTALDH1A1 | |
| SCHEMBL17098618 | 0.94 | CCR5 (0.38) | CCR5NR3C1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL17098615 | 0.94 | CCR5 (0.38) | CCR5NR3C1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL17097874 | 0.94 | CCR5 (0.33) | CCR5ALDH1A1SMN1; SMN2TAS2R14HSD11B1 | |
| SCHEMBL17097870 | 0.94 | CCR5 (0.33) | CCR5ALDH1A1SMN1; SMN2TAS2R14HSD11B1 | |
| SCHEMBL17098647 | 0.93 | TAS2R14 (0.34) | CCR5MAPTALDH1A1SMN1; SMN2TAS2R14 | |
| SCHEMBL17048997 | 0.93 | TAS2R14 (0.34) | CCR5MAPTALDH1A1SMN1; SMN2TAS2R14 | |
| SCHEMBL17098334 | 0.93 | CCR5 (0.33) | CCR5ALDH1A1SMN1; SMN2TAS2R14HSD11B1 | |
| SCHEMBL17097855 | 0.93 | TAS2R14 (0.34) | CCR5MAPTALDH1A1SMN1; SMN2TAS2R14 | |
| SCHEMBL17098337 | 0.93 | CCR5 (0.33) | CCR5ALDH1A1SMN1; SMN2TAS2R14HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | claimed |
| EP-3110810-B1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | CCR5 597/4885NR3C1 66/4885POLB 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.